Twin Focus Capital Partners, LLC Bristol Myers Squibb CO Transaction History

Twin Focus Capital Partners, LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $19,192 - $21,760	-400 Reduced 7.33%	5,054 $274,000
Q4 2023 Mar 05, 2024	SELL	$48.48 - $57.85 $48,673 - $58,081	-1,004 Reduced 15.55%	5,454 $279,000
Q4 2023 Feb 13, 2024	BUY	$48.48 - $57.85 $57,400 - $68,494	1,184 Added 22.45%	6,458 $331,000
Q3 2023 Nov 13, 2023	SELL	$57.89 - $64.73 $179,343 - $200,533	-3,098 Reduced 37.0%	5,274 $306,000
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $163,479 - $181,518	2,566 Added 44.2%	8,372 $535,000
Q1 2023 May 12, 2023	BUY	$65.71 - $74.53 $3,351 - $3,801	51 Added 0.89%	5,806 $402,000
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $2,807 - $3,324	41 Added 0.72%	5,755 $414,000
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $7,992 - $9,583	130 Added 2.33%	5,714 $417,000
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $54,809 - $63,895	1,022 Added 22.4%	5,584 $348,000
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $2,603 - $3,049	44 Added 0.97%	4,562 $270,000
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $279,709 - $304,603	4,518 New	4,518 $302,000
Q1 2021 May 12, 2021	SELL	$59.34 - $66.74 $220,566 - $248,072	-3,717 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $214,619 - $243,203	3,717 New	3,717 $231,000
Q2 2020 Aug 12, 2020	SELL	$54.82 - $64.09 $427,321 - $499,581	-7,795 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $4,825 - $7,012	104 Added 1.35%	7,795 $434,000
Q4 2019 Feb 13, 2020	BUY	$49.21 - $64.19 $97,681 - $127,417	1,985 Added 34.79%	7,691 $494,000
Q3 2019 Nov 07, 2019	BUY	$42.77 - $50.71 $244,045 - $289,351	5,706 New	5,706 $289,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.